If I take it right the pharma ip won't have to provide financial data on authorization and they can continue to sell their medicines while waiting for reauthorization.
The ability to authorize those medicines still lie in our hand.
Since you seem to be incapable of comprehending long post, I'm going to make it short in favor of my friend
My point is: "The mid-high tech and pharma native industry in Vietnam is non-existent, thus they cannot be harmed by tpp trade deal."
My proof is the very list of export/import that you...